GPR162 is an orphan G protein-coupled receptor of the Rhodopsin (Class A) family with emerging physiological roles in metabolism and neuroendocrine function. Based on phylogenetic analysis, GPR162 is predicted to bind catecholamines (adrenaline and noradrenaline) 1. Recently, GPR162 was identified as the cognate receptor for cocaine and amphetamine-regulated transcript (CART) in pancreatic beta cells, where CART binding to GPR162 mediates insulin secretion and regulates cytoskeletal arrangement 2. GPR162 is widely expressed in the hypothalamus and other brain regions involved in energy homeostasis, including the hippocampus, amygdala, and ventral tegmental area 3. In rodent studies, GPR162 knockdown decreased food intake, and human genetic variants in GPR162 were associated with impaired glucose homeostasis 3. Clinically, loss-of-function variants in GPR162 have been identified in pituitary corticotroph adenomas, where reduced GPR162 function led to increased pro-opiomelanocortin (POMC) transcription and tumor development 4. Additionally, GPR162 downregulation was identified as a prognostic biomarker associated with decreased overall survival in glioblastoma patients 5. These findings position GPR162 as a multifunctional neuroendocrine receptor with potential roles in metabolic regulation and tumor suppression.